Compare Inovio Pharmaceuticals Inc (INO) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Health Care Select Sector SPDR Fund — how do they compare? Inovio Pharmaceuticals Inc trades at $0.79 (market cap $78.55M), while Health Care Select Sector SPDR Fund trades at $168.42. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | XLV | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | — |
52-Week High | $2.87 | $168.44 |
52-Week Low | $0.66 | $131.16 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
XLV, the Health Care Select Sector SPDR ETF, trades at $168.44 with a neutral daily change. Technical indicators show a bullish trend from moving averages but oscillators are neutral, with the 6-day RSI at 86.78 suggesting overbought conditions. The fund's low 0.08% expense ratio and defensive healthcare sector exposure attract steady inflows amid market volatility, as highlighted by recent ETF flow reports.
The outlook for XLV is cautiously optimistic, supported by defensive demand and strong sector earnings. Key opportunities include diversification benefits and cost efficiency, while risks involve sector-specific regulatory pressures and broader economic sensitivity. Investors should weigh the ETF's stability against potential growth limitations in a concentrated portfolio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
